key: cord-0824157-fqy7uuka
authors: Feehan, Amy K.; Fort, Daniel; Velasco, Cruz; Burton, Jeffrey H.; Garcia-Diaz, Julia; Price-Haywood, Eboni G.; Sapp, Eric; Pevey, Dawn; Seoane, Leonardo
title: The importance of anosmia, ageusia and age in community presentation of symptomatic and asymptomatic SARS-CoV-2 infection in Louisiana, USA; a cross-sectional prevalence study
date: 2021-01-06
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.12.029
sha: 53c486326254e533cb855a200b4bfd5301008469
doc_id: 824157
cord_uid: fqy7uuka

OBJECTIVE: While many seroprevalence studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been performed, few are demographically representative. This investigation focused on defining the nature and frequency of symptomatic and asymptomatic SARS-CoV-2 infection in a representative, cross-sectional sample of communities in Louisiana, USA. METHODS: A sample of 4,778 adults from New Orleans and Baton Rouge, Louisiana were given a survey of symptoms and comorbidities, nasopharyngeal swab to test for an active infection (PCR), and blood draw to test for a past infection (immunoglobulin G). Odds ratios, cluster analysis, quantification of virus and antibody, and linear modeling were used to understand whether certain symptoms were associated with a positive test, how symptoms grouped together, whether virus or antibody varied by symptom status, and whether being symptomatic was different across the age span. RESULTS: Reported anosmia/ageusia was strongly associated with a positive test; 40.6% (93/229) tested positive versus 4.8% (218/4,549) positivity in those who did not report anosmia/ageusia (Common OR: 13.6; CI 10.1, 18.3). Of the people who tested positive, 47.3% (147/311) were completely asymptomatic. Symptom presentation clustered into three groups; low/no symptoms (0.4±0.9 average ±SD), highly symptomatic (7.5±1.9) or moderately symptomatic (4.0±1.5). Quantity of virus was lower in the asymptomatic versus symptomatic group (cycle number 23.3±8.3 versus 17.3±9.0, average ±SD; p<0.001). Modeling the probability of symptoms showed changes with age; the highest probability of reporting symptoms was 64.6% (CI 50.4-76.5) at age 29 which decreased to a probability of 49.3% (CI 36.6-62.0) at age 60 and only 25.1% (CI 5.0-68.1) at age 80. CONCLUSION: Anosmia/ageusia can be used to differentiate SARS-CoV-2 infection from other illnesses, and, given the high ratio of asymptomatic individuals, contact tracing should include those without symptoms. Regular testing in congregant settings of those over age 60 may help mitigate asymptomatic spread.

of symptoms and comorbidities, nasopharyngeal swab to test for an active infection (PCR), and blood 23 draw to test for a past infection (immunoglobulin G). Odds ratios, cluster analysis, quantification of virus 24 and antibody, and linear modeling were used to understand whether certain symptoms were associated 25 with a positive test, how symptoms grouped together, whether virus or antibody varied by symptom 26 status, and whether being symptomatic was different across the age span. Symptom presentation clustered into three groups; low/no symptoms (0.4±0.9 average ±SD), highly 31 symptomatic (7.5±1.9) or moderately symptomatic (4.0±1.5). Quantity of virus was lower in the 32 asymptomatic versus symptomatic group (cycle number 23.3±8.3 versus 17.3±9.0, average ±SD; 33 p<0.001). Modeling the probability of symptoms showed changes with age; the highest probability of 34 reporting symptoms was 64.6% (CI 50.4-76.5) at age 29 which decreased to a probability of 49.3% (CI 35

Prevalence studies have been conducted worldwide to understand the true spread of SARS-CoV-2. There 42 are several strategies for surveillance, but the quickest way to survey the population is to obtain blood 43 remnants from labs or blood banks that collect a high volume of samples and test for antibodies. [1-11] 44 This method offers a quick turnaround at a low cost with minimal data, usually sex, age, and region of 45 collection. However, this sample skews heavily toward 1) people who regularly interact with healthcare 46

or 2) those who are healthy enough to give blood. This method gives no information regarding symptoms 47 or demographics, which may be important to understand how variable the presentation and spread of 48 For this study, we developed a novel recruitment system with Public Democracy (Arlington, Virginia) to 57 ensure a representative sample through a stratified random selection process. We administered a survey of 58 symptoms and comorbidities, collected a nasopharyngeal (NP) swab to assess active viral infection, and 59 collected blood to assess immunoglobulin G (IgG). We distinguished significant racial disparities and ZIP 60 code-level variation in spread of the virus. [28,29] The objective of this report is to tabulate the nature and 61 frequency of symptoms in community presentation of SARS-CoV-2 infection in Louisiana using odds 62 ratios to estimate odds of positivity by symptom, cluster analysis to see how symptoms tend to group 63 together, quantification of virus by symptom status and disease stage to determine differences, and a 64 logistic regression model to understand how symptoms are reported by age. We hypothesize that similarly Abbott instrumentation was used for both nucleic acid (NP swabs) and antibody (serum) tests for SARS-90

CoV-2 infection. Real-time reverse transcriptase polymerase chain reaction (PCR) tests (NP swabs) were 91 performed on the Abbott m2000 RealTime system (100 cps/mL limit of detection), and cycle number 92 (CN) was collected by the lab. Qualitative IgG blood tests were performed on the ARCHITECT i2000SR 93 (99.63% specificity and 100% sensitivity, nucleocapsid target), and sample to calibrator ratio (S/C) was 94 collected by the lab. Both tests are US Food and Drug Administration-Emergency Use Authorization 95 approved, and the antibody test meets the criteria described by the CDC to yield high positive predictive 96 value. [6] No cross-reaction with other coronaviruses and common respiratory viruses is reported. 97

The number reporting symptoms and comorbidities in the total sample and those who tested positive are 98 tabulated in Table 1 . Prevalence for each factor was calculated as the number with a positive test divided 99 by the total reporting each factor. To determine which symptoms and comorbidities were associated with 100 a positive test, we carried out a Cochran-Mantel-Haenszel (CMH) analysis and estimated common odds 101 ratios across cities. Validity of the combined city approach was confirmed by negligible observed city-102 level variation in multilevel models with a random city effect. City-specific and common odds ratios from 103 the CMH analysis are displayed with 95% confidence intervals in sFigure 3. Corresponding p-values from 104 homogeneity tests are presented for each. Viral and IgG quantity was averaged by probable disease stage 105 ( PCR+/IgG-, contagious; PCR+/IgG+, early recovery; and PCR-/IgG+, recovered) and symptom status 106 within that disease stage to determine whether the amount of virus or antibody was different among these 107 groups. Binary (1/0) symptom data for all patients were hierarchically clustered and plotted using the 108 Ward method and Gower distance in R (hclust, dendextend packages) to determine whether distinct, 109 patient-reported symptom presentations were present. Demographic and comorbidity data were compared 110 by symptom cluster using exact confidence intervals and p-values from the exact chi-square homogeneity 111 test for categorical variables, and ANOVA with unequal variances or Kruskal-Wallis scores test for 112 continuous or ordinal variables. To determine whether symptomatic or asymptomatic presentation was 113 different across the age span, modeling of the probability of reporting symptoms by age was performed using a logistic regression with cubic splines and 4 nodes. Statistical analyses were carried out in SAS 115 STAT 14.2. 116

A total of 4,778 subjects were analyzed; 2,640 from New Orleans and 2,138 from Baton Rouge. The Symptoms and comorbidities captured in the survey are listed in Table 1 and sFigure 2, and the common 123 odds ratios (OR: 95% CI) are reported in Figure 1 . Overall, 25.6% (1,223/4,778) of participants reported 124 symptoms, and over half of all positive participants were symptomatic (52.7%, 164/311) Of those who 125 were symptomatic, prevalence was 13.4% (164/ 1,223). Anosmia/ageusia was reported by only 4.8% 126 (229/4,778) of the sample but was present in 29.9% (93/311) of positive cases with a prevalence of 40.6% 127 (93/229), making it a standalone symptom with 13.6 times higher odds of testing positive versus those 128 who did not report anosmia/ageusia. Other symptom ORs ranged from 2.2 (CI 1.66, 3.02) for sore throat 129 to 3.9 (CI 2.95, 5.09) for fever. ORs were homogeneous between cities for most factors, except for 130 anosmia (p=0.0290), comorbidity group Other (p=0.0193), and No Comorbidities (p=0.0232) (sFigure 3). By using representative sampling, a survey of symptoms, and antibody testing with paired PCR, we were 166 able to determine the prevalence of symptomatic and asymptomatic SARS-CoV-2 infection infections in 167 the community. This study found that 47.3% (147/311) of infections were asymptomatic, 29.9% (93/311) 168 of positive cases reported anosmia/ageusia (Table 1) , and those who reported anosmia/ageusia had higher 169 odds of testing positive versus any other symptomatic group (Figure 1) Orleans, USA and found 50% asymptomatic infections and 28.2% of positive people reporting 174 anosmia/ageusia. [22] A study of individuals in London, UK with a loss of smell and/or taste found that 175 antibody prevalence was even higher (78%) if testing was solely focused on anosmia/ageusia, which 176 underscores the specificity of this symptom for SARS-CoV-2 infection despite methodological 177 differences between these studies. cluster commonly reported fatigue and myalgia, but anosmia/ageusia and fever were also highly present. 200

Nearly half of this cluster could have been prioritized for SARS-CoV-2 testing because anosmia/ageusia, 201 or perhaps in lieu of other testing (e.g. influenza) in resource-limited settings. 202

Finally, the non-linear relationship between age and probability of reporting symptoms was surprising. 203

Anecdotally, younger individuals were thought to be asymptomatic more often, but our model 204 demonstrates the opposite. Those 60 years of age and older had a lower probability of reporting 205 symptoms, which could be a public health concern in nursing homes and assisted living facilities, where 206 the disease may silently spread. Of those who were symptomatic, anosmia/ageusia was highly detectable. 207

This study relies on self-report data and there are many unknowns about biological factors that could 208 impact antibody development, which could impact our results. This report does not include those who 209 were critically ill, living in nursing homes, or children and excludes symptom presentation in emergency 210 departments or hospitals. There is a chance that someone reported symptoms from a non-COVID illness, 211 actually had an asymptomatic infection, received an IgG+ result and was incorrectly classified as 212 symptomatic, or that someone had a low symptomatic response and forgot, causing them to report no symptoms. Additionally, there is a chance that those in the initial stages of disease were presymptomatic 214 and went on to have symptoms later. 215

In conclusion, anosmia/ageusia seems to be a hallmark of COVID-19 even in the cluster of symptoms that 216 represents low or no symptoms. Given the high likelihood of someone with anosmia/ageusia testing 217 positive, people experiencing this symptom should be encouraged to quarantine and/or receive a test, and 218 screening for this symptom should be implemented for those at high risk. Given the high proportion of 219 asymptomatic infections, long-term outcomes should be studied to determine if there are associated 220 lasting risks. Contact tracing should include testing people who do not have symptoms, especially those 221 over age 60 as part of a public health strategy. 222

Funding: This work was supported by ReNOLA, that funded the recruitment effort by Public 224

Democracy, and by Ochsner Health that funded the rest of the New Orleans portion of the study. 

SARS-CoV-2 seroprevalence 262 and neutralizing activity in donor and patient blood

SARS-CoV-2 seroprevalence 264 trends in healthy blood donors during the COVID-19 Milan outbreak

Covid-19 Seroprevalence rate 267 in healthy blood donors from a community under strict lockdown measures

SARS-CoV-2 IgG seroprevalence in blood donors located in three 270 different federal states

Estimation of seroprevalence of novel 272 coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-273 sectional study

Repeated cross-sectional 275 sero-monitoring of SARS-CoV-2 in New York City

Seroprevalence of Antibodies 277 to SARS-CoV-2 in 10 Sites in the United States

SARS-CoV-2 279 antibody prevalence in Brazil: results from two successive nationwide serological household surveys

Infection fatality rate 285 of SARS-CoV-2 infection in a German community with a super-spreading event

Seroprevalence of SARS-CoV-288 2-Specific Antibodies Among Adults

A population-291 based study of the prevalence of COVID-19 infection in Espirito Santo, Brazil: methodology and results 292 of the first stage

Performance 294 Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in

Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'

Seroprevalence of 301 SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening

Community Seroprevalence of SARS-CoV-2 Antibodies -Two Georgia Counties

Serology-informed 310 estimates of SARS-CoV-2 infection fatality risk in

Population-312 based surveys of antibodies against SARS-CoV-2 in Southern Brazil

Seroprevalence of 314 anti-SARS-CoV-2 IgG antibodies in

seroprevalence in the municipality of Sao Paulo, Brazil, ten weeks after the first reported case

Low 320 prevalence of active COVID-19 in Slovenia: a nationwide population study of a probability

Seroprevalence of 323 SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes

Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus

CoV-2) infection in humans: A systematic review and series of meta-analyses

Seroprevalence of 333 SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-334 based population in London, UK: An observational cohort study

Clinical and immunological assessment of 336 asymptomatic SARS-CoV-2 infections

The authors would like to especially thank the labs at the Ochsner Medical Center

J o u r n a l P r e -p r o o f